Superstring Capital Management
Latest statistics and disclosures from Superstring Capital Management's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0001931118
Tip: Access up to 7 years of quarterly data
Positions held by Superstring Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Superstring Capital Management
Superstring Capital Management holds 30 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| ImmunoGen | 12.7 | $18M | 598k | 29.65 |
|
|
| Cytokinetics Com New (CYTK) | 10.6 | $15M | 178k | 83.49 |
|
|
| 89bio (ETNB) | 8.1 | $11M | 1.0M | 11.17 |
|
|
| Ionis Pharmaceuticals (IONS) | 6.8 | $9.6M | 190k | 50.59 |
|
|
| Ideaya Biosciences (IDYA) | 6.4 | $8.9M | 251k | 35.58 |
|
|
| Protagonist Therapeutics (PTGX) | 6.2 | $8.7M | 379k | 22.93 |
|
|
| Immunovant (IMVT) | 6.1 | $8.6M | 204k | 42.13 |
|
|
| Bridgebio Pharma (BBIO) | 5.9 | $8.3M | 206k | 40.37 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 4.0 | $5.5M | 380k | 14.60 |
|
|
| Marinus Pharmaceuticals Com New (MRNS) | 3.6 | $5.0M | 462k | 10.87 |
|
|
| Neurocrine Biosciences (NBIX) | 2.8 | $3.9M | 29k | 131.76 |
|
|
| Urogen Pharma (URGN) | 2.7 | $3.8M | 255k | 15.00 |
|
|
| Savara (SVRA) | 2.7 | $3.8M | 814k | 4.70 |
|
|
| Roivant Sciences SHS (ROIV) | 2.6 | $3.7M | 326k | 11.23 |
|
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 2.4 | $3.4M | 55k | 62.00 |
|
|
| Fate Therapeutics (FATE) | 2.3 | $3.2M | 848k | 3.74 |
|
|
| Keros Therapeutics (KROS) | 2.1 | $3.0M | 75k | 39.76 |
|
|
| Acelyrin (SLRN) | 1.9 | $2.7M | 357k | 7.46 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 1.8 | $2.5M | 124k | 19.88 |
|
|
| Nkarta (NKTX) | 1.6 | $2.3M | 347k | 6.60 |
|
|
| Krystal Biotech (KRYS) | 1.4 | $2.0M | 16k | 124.06 |
|
|
| Quanterix Ord (QTRX) | 1.4 | $2.0M | 72k | 27.34 |
|
|
| Axsome Therapeutics (AXSM) | 0.9 | $1.3M | 16k | 79.59 |
|
|
| So Young International Sponsored Ads (SY) | 0.7 | $1.0M | 796k | 1.26 |
|
|
| Immatics SHS (IMTX) | 0.6 | $834k | 79k | 10.53 |
|
|
| Allogene Therapeutics (ALLO) | 0.5 | $713k | 222k | 3.21 |
|
|
| Inozyme Pharma (INZY) | 0.4 | $528k | 124k | 4.26 |
|
|
| Fusion Pharmaceuticals (FUSN) | 0.3 | $440k | 46k | 9.61 |
|
|
| Spruce Biosciences (SPRB) | 0.2 | $348k | 119k | 2.93 |
|
|
| Ys Biopharma Ordinary Shares (YS) | 0.1 | $166k | 308k | 0.54 |
|
Past Filings by Superstring Capital Management
SEC 13F filings are viewable for Superstring Capital Management going back to 2023
- Superstring Capital Management 2023 Q4 filed Feb. 14, 2024